The second pharmaceutical enterprise in France is a newly established company after the merger of Sanofi (a subsidiary of the former famous oil giant ELF) and Saint-Deleux (a subsidiary of L 'Oré al France) in 1999.
In 2004 1 month, Sanofi Synthetic Company acquired competitor Aventis and established a new Sanofi Aventis Company (pronounced Sanofi Aventis). The new enterprise has become the third largest pharmaceutical company in the world after Pfizer in the United States and GlaxoSmithKline in the United Kingdom.
Management:
Dai Heke, CEO
Gé rard Lefour, Senior Executive Vice President
Shareholder details: Total S.A holds 12.65%, and L 'Oré al holds 8.7%.
Treasury shares hold 5.47%, employees hold 1.29%, and the remaining 70.46% are public shares.
Distribution of power: Total holds 2 1.37%, L 'Oré al holds 2 1.37%, employees hold 1.54%, and other shareholders hold 59.97%.
Income Status = = = In 2006, the total sales of Sanofi-Aventis was 28 billion euros.